Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anti-cancer agents and uses thereof

a technology of anti-cancer agents and active ingredients, applied in the field of anti-cancer agents, can solve the problems of unchecked cell growth and proliferation leading to cancer development, and achieve the effect of hindering or blocking the cell cycle progression

Inactive Publication Date: 2009-04-09
LOCUS PHARMA INC
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Deregulation of the cell cycle by altering key enzymatic and genetic steps can lead to unchecked cell growth and proliferation leading to cancer development.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-cancer agents and uses thereof
  • Anti-cancer agents and uses thereof
  • Anti-cancer agents and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

1,3-DIBROMO-5-NITROBENZENE

[0387](The named compound was synthesized according to Dumont, Bull. Soc. Chim. Bel., 505 (1995). This compound is also commercially available from Karl Industries, Aurora, Ohio) To a suspension of 2,6-dibromo-4-nitroaniline (75.0 g, 254 mmol) in ethanol (1 L) was added H2SO4 (100 mL). The mixture was heated to reflux and sodium nitrite (50.5 g, 730 mmol) was added portion-wise over a period of 15 min. The mixture was heated at reflux for 3 h and was then cooled to room temperature. The formed thick suspension was poured on ice water (1000 mL) upon which more solid precipitated. The solid was filtered and the filter cake washed with water (2×250 mL) and dried in an oven at 20 mbar / 30° C. to give 66.2 g (93%) of 1,3-dibromo-5-nitrobenzene as a brown solid.

example 2

3,5-DIBROMO-1-BENZYLOXYBENZENE

[0388](According to Effenberger, Chem. Ber. 163 (1991).) 1,3-dibromo-5-nitrobenzene (2.81 g, 10.0 mmol), freshly powdered potassium hydroxide (1.00 g, 17.8 mmol) and tetrabutylammonium bromide (0.32 g, 1.00 mmol) were dissolved in tetramethyl urea (TMU, 8 mL). Oxygen was bubbled through the reaction mixture for 5 min and a solution of benzyl alcohol (1.30 g) in TMU (2 mL) was added drop-wise at room temperature over a period of 1 h. The mixture was stirred for 6 h at room temperature during which oxygen was bubbled through. The reaction mixture was poured on ice (30 g) and was extracted with tert-butylmethyl ether (2×50 mL). The combined organics were dried (MgSO4) and concentrated to give the crude product which was purified by FC (120 g SiO2, AcOEt / heptane 1:4) to provide 3.15 g (92%) of 3,5-dibromo-1-benzyloxybenzene.

example 3

3,5-DIBROMO-1-P-METHOXY-BENZYLOXYBENZENE

[0389]1,3-dibromo-5-nitrobenzene (30.0 g, 107 mmol), freshly powdered potassium hydroxide (10.8 g, 192 mmol) and tetrabutylammonium bromide (3.42 g, 10.7 mmol) were dissolved in tetramethyl urea (TMU, 90 mL). A solution of p-methoxybenzyl alcohol (17.8 g, 128 mmol) in TMU (30 mL) was added drop-wise at room temperature over a period of 1 h. The mixture was stirred for 48 h at room temperature. The reaction mixture was poured on ice (160 g) and was extracted with tert-butylmethyl ether (4×200 mL). The combined organics were dried (MgSO4) and concentrated to give the crude product which was purified by FC (2.5 kg SiO2, AcOEt / heptane 1:9) to provide 29.6 g of 3,5-dibromo-1-p-methoxy-benzyloxybenzene which was not completely pure but which crystallized upon standing. The solid was taken up in methanol (27 mL) and the formed slurry was stirred at 60° C. for 10 min. The suspension was cooled to 0-5° C. and was then filtered. The filter cake was wash...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I:and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.

Description

[0001]This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Appl. No. 60 / 498,705, filed Aug. 29, 2003, and of U.S. Provisional Appl. No. 60 / 528,695, filed Dec. 12, 2003, both of which are hereby incorporated by reference in their entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents.[0004]2. Related Art[0005]The cell cycle is a normal, highly regulated ordered set of events that culminates in cell growth and division. The cell cycle progresses through a protein synthetic phase (G1), a DNA synthetic phase (S) and a mitotic stage (G2 / M). Deregulation of the cell cycle by altering key enzymatic and genetic steps can lead to unchecked cell growth and proliferation leading to cancer development.[0006]Blocking the cell cycle with pharmacological inhibitors of key molecular targets that drive the cell cycle through mit...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/5377C07D401/02C07D211/80C07D409/02C07D401/14C07D405/02A61K31/497A61K31/506A61P35/00A61K31/422A61K31/4709A61K31/4439A61K31/4436A61K31/443A61K31/44C07D413/02
CPCC07D209/08C07D213/74C07D401/10C07D401/12C07D401/14C07D417/10C07D403/12C07D405/10C07D405/12C07D409/12C07D409/14C07D403/10A61P35/00
Inventor KELLY, MARTHALEE, YOUNGHEELIU, BINFUJIMOTO, TEDFREUNDLICH, JOELDORSEY, BRUCE D.FLYNN, GARY A.HUSAIN, ARIFA
Owner LOCUS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com